Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that ...

Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 ...

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.

Market Domination host Josh Lipton takes a look at some of Tuesday's trending tickers and stories. Homebuilder stocks, ...

Novo, which makes Ozempic and Wegovy, said it expected sales to fall by between 5% and 13% this year compared with growth of ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% ...

Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for ...

Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government’s push to cut drug prices in country, will contribute to the decline, the company said. The warning ...

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly ...